GLP-1 (Glucagon-Like Peptide-1)
An incretin hormone secreted by intestinal L-cells in response to nutrient ingestion. GLP-1 stimulates insulin secretion, suppresses glucagon, slows gastric emptying, and promotes satiety. GLP-1 receptor agonists like semaglutide and tirzepatide mimic this hormone for type 2 diabetes and weight management.
What does GLP-1 (Glucagon-Like Peptide-1) mean in peptide research?
An incretin hormone secreted by intestinal L-cells in response to nutrient ingestion. GLP-1 stimulates insulin secretion, suppresses glucagon, slows gastric emptying, and promotes satiety. GLP-1 receptor agonists like semaglutide and tirzepatide mimic this hormone for type 2 diabetes and weight management. This term is part of the broader field of peptide research, which encompasses both FDA-approved therapeutic peptides and research-grade compounds used in scientific investigation.
Why this term matters
Understanding GLP-1 (Glucagon-Like Peptide-1) is foundational for anyone reviewing peptide research literature, comparing different research compounds, or following regulatory developments in this field. The term appears across pharmacology textbooks, FDA documentation, and clinical trial reports.
Where to learn more
For deeper context, see our peptide research articles: